V. A. Zhmurov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
V. A. Zhmurov has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Pavel B. Zotov
Tyumen State Medical University
5 shared publications Ermakova A.A. Ermakova
4 shared publicationsZhmurov D.V. Zhmurov
4 shared publicationsZhmurova E.A. Zhmurova
4 shared publications- Denis V. Zhmurov
Tyumen State Medical University
3 shared publications - E. A. Mateykovich
Tyumen State Medical University; Perinatal Medical Center
3 shared publications
Latest Publications
- 26 July 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (2) , 82-87
Pharmacoeconomic effect of Escherichia coli bacterial lysate in combination therapy for chronic pyelonephritis in the active infl ammatory phase
In recent decades, urinary tract infections (UTIs) have become a leading cause of bacterial infections, posing a threat to human life and health. Chronic pyelonephritis, in particular, is the leading cause of chronic kidney disease.Given the multifactorial pathogenesis of chronic pyelonephritis (CPN), a multidisciplinary approach is crucial in the treatment of this disease. This justifies the need to determine the antimicrobial efficacy of new generations of antibacterial and immunomodulatory drugs, including lyophilized E. coli bacterial lysate, aimed at preventing the progression of CPN and achieving long-term disease remission.
- 26 July 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (2) , 82-87
Pharmacoeconomic effect of Escherichia coli bacterial lysate in combination therapy for chronic pyelonephritis in the active infl ammatory phase
In recent decades, urinary tract infections (UTIs) have become a leading cause of bacterial infections, posing a threat to human life and health. Chronic pyelonephritis, in particular, is the leading cause of chronic kidney disease.Given the multifactorial pathogenesis of chronic pyelonephritis (CPN), a multidisciplinary approach is crucial in the treatment of this disease. This justifies the need to determine the antimicrobial efficacy of new generations of antibacterial and immunomodulatory drugs, including lyophilized E. coli bacterial lysate, aimed at preventing the progression of CPN and achieving long-term disease remission.
- Open Access
- 25 June 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 247-255
Comparative analysis of the use of phosphate-binding drugs in patients receiving hemodialysis
Introduction. Chronic kidney disease (CKD) is a widespread, non-communicable chronic condition that leads to a significant deterioration in quality of life and high mortality among patients. Hyperphosphatemia is an independent factor in increasing all-cause and cardiovascular mortality at all stages of CKD. Aim. To comparatively evaluate the efficacy of calcium-free phosphate binders (sevelamer carbonate and beta-iron(III) oxyhydroxide complex of sucrose and starch) in patients receiving hemodialysis. Mat erials and methods. A retrospective analysis of 94 medical records of patients with end-stage CKD receiving renal replacement therapy was conducted. Inclusion criteria: Patients aged 18 to 85 years with end-stage CKD, undergoing hemodialysis for 12 months and receiving phosphate binders. Results. In the total group of patients (94 people), statistically significant changes in phosphorus levels were observed over the course of the year-long observation period (p = 0.001). In the first group of patients taking beta-iron (III) sucrose oxyhydroxide starch complex, a statistically significant decrease in phosphorus levels over time (p = 0.046) (Friedman test used). In the second group of patients receiving sevelamer carbonate, a statistically significant change was also observed (p < 0.001) (Friedman test used). When assessing the additional effects of phosphate binders, statistically significant changes were found across the two study drug groups: increased blood albumin levels (p < 0.001) and increased transferrin levels (p < 0.001). Statistically significant changes in cholesterol reduction were found in the sevelamer carbonate group (p = 0.044). The Friedman test was used in the assessments. No statistically significant changes were found in C-reactive protein or ferritin levels in the two study groups. Conclusion. Our studies of the effectiveness of phosphate-binding therapy showed that in both groups there were positive changes in the normalization of phosphorus levels in the blood throughout the entire period and were statistically significant in both comparison groups.
- 25 June 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 247-255
Open AccessComparative analysis of the use of phosphate-binding drugs in patients receiving hemodialysis
Introduction. Chronic kidney disease (CKD) is a widespread, non-communicable chronic condition that leads to a significant deterioration in quality of life and high mortality among patients. Hyperphosphatemia is an independent factor in increasing all-cause and cardiovascular mortality at all stages of CKD. Aim. To comparatively evaluate the efficacy of calcium-free phosphate binders (sevelamer carbonate and beta-iron(III) oxyhydroxide complex of sucrose and starch) in patients receiving hemodialysis. Mat erials and methods. A retrospective analysis of 94 medical records of patients with end-stage CKD receiving renal replacement therapy was conducted. Inclusion criteria: Patients aged 18 to 85 years with end-stage CKD, undergoing hemodialysis for 12 months and receiving phosphate binders. Results. In the total group of patients (94 people), statistically significant changes in phosphorus levels were observed over the course of the year-long observation period (p = 0.001). In the first group of patients taking beta-iron (III) sucrose oxyhydroxide starch complex, a statistically significant decrease in phosphorus levels over time (p = 0.046) (Friedman test used). In the second group of patients receiving sevelamer carbonate, a statistically significant change was also observed (p < 0.001) (Friedman test used). When assessing the additional effects of phosphate binders, statistically significant changes were found across the two study drug groups: increased blood albumin levels (p < 0.001) and increased transferrin levels (p < 0.001). Statistically significant changes in cholesterol reduction were found in the sevelamer carbonate group (p = 0.044). The Friedman test was used in the assessments. No statistically significant changes were found in C-reactive protein or ferritin levels in the two study groups. Conclusion. Our studies of the effectiveness of phosphate-binding therapy showed that in both groups there were positive changes in the normalization of phosphorus levels in the blood throughout the entire period and were statistically significant in both comparison groups.
- 9 June 2026
- Published by LLC M-Center in Суицидология
- Vol. 17 (01(62))
INTIMATE PARTNER VIOLENCE AMONG SUICIDE RISK FACTORS IN WOMEN
- 9 June 2026
- Published by LLC M-Center in Суицидология
- Vol. 17 (01(62))
INTIMATE PARTNER VIOLENCE AMONG SUICIDE RISK FACTORS IN WOMEN
- 9 March 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (1) , 90-93
Comparative analysis of the effect of lisinopril and valsartan on the results of dynamic nephroscintigraphy in chronic pyelonephritis with arterial hypertension
Bacterial infections currently pose a threat to human health, and in some cases, life. Urinary tract infections are a significant threat among them. Chronic pyelonephritis (chrPN), as a common cause of chronic kidney disease (CKD), is of significant importance in this regard. THE AIM : to study the clinical and functional effects of antihypertensive drugs in patients with symptomatic arterial hypertension (AH) in the early stages of CKD due to chrPN, using a comparative analysis using dynamic renal scintigraphy. PATIENT AND METHODS . Our study included 100 patients with CPN and hypertension, CKD C1-C3a, in remission. RESULTS . Target blood pressure was achieved with ACE inhibitors and ARBs for 2 months. Estimated glomerular filtration rate (eGFR) did not change significantly. Lisinopril therapy had no effect on Tmax and Tmax–T½ in both kidneys. Improvement in secretory and excretory function in both kidneys was observed with valsartan. CONCLUSION . A positive effect of valsartan was observed, suggesting it as a more promising drug for renal protection in patients with chronic kidney disease and hypertension.
- 9 March 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 30 (1) , 90-93
Comparative analysis of the effect of lisinopril and valsartan on the results of dynamic nephroscintigraphy in chronic pyelonephritis with arterial hypertension
Bacterial infections currently pose a threat to human health, and in some cases, life. Urinary tract infections are a significant threat among them. Chronic pyelonephritis (chrPN), as a common cause of chronic kidney disease (CKD), is of significant importance in this regard. THE AIM : to study the clinical and functional effects of antihypertensive drugs in patients with symptomatic arterial hypertension (AH) in the early stages of CKD due to chrPN, using a comparative analysis using dynamic renal scintigraphy. PATIENT AND METHODS . Our study included 100 patients with CPN and hypertension, CKD C1-C3a, in remission. RESULTS . Target blood pressure was achieved with ACE inhibitors and ARBs for 2 months. Estimated glomerular filtration rate (eGFR) did not change significantly. Lisinopril therapy had no effect on Tmax and Tmax–T½ in both kidneys. Improvement in secretory and excretory function in both kidneys was observed with valsartan. CONCLUSION . A positive effect of valsartan was observed, suggesting it as a more promising drug for renal protection in patients with chronic kidney disease and hypertension.
- 3 March 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (12) , 921-926
Atypical hemolytic-uremic syndrome
A clinical case of atypical hemolytic uremic syndrome in an adult man is presented. Atypical hemolytic uremic syndrome (aHUS) is an orphan disease that affects various organs and systems and is accompanied by extremely high mortality. aHUS is based on uncontrolled activation of the alternative complement pathway, leading to generalized thrombus formation in the vessels of the microcirculatory bed. High mortality in aHUS is due to several reasons: extremely rare incidence of the disease and, as a result, low awareness of it by doctors, nonspecific symptoms at the onset of aHUS, rapid development of multiple organ failure with kidney damage due to catastrophic generalized thrombus formation in the microcirculatory bed.
- 3 March 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (12) , 921-926
Atypical hemolytic-uremic syndrome
A clinical case of atypical hemolytic uremic syndrome in an adult man is presented. Atypical hemolytic uremic syndrome (aHUS) is an orphan disease that affects various organs and systems and is accompanied by extremely high mortality. aHUS is based on uncontrolled activation of the alternative complement pathway, leading to generalized thrombus formation in the vessels of the microcirculatory bed. High mortality in aHUS is due to several reasons: extremely rare incidence of the disease and, as a result, low awareness of it by doctors, nonspecific symptoms at the onset of aHUS, rapid development of multiple organ failure with kidney damage due to catastrophic generalized thrombus formation in the microcirculatory bed.
- Open Access
- 22 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (4S) , 4737
Academic schools of internal and preventive medicine: vectors for the development of physician professionalism
This article defines the role of academic schools of internal and preventive medicine in the unified educational environment for training physicians in the field of internal medicine. The 5 th International Research and Practice Forum "Academic Schools of Internal and Preventive Medicine" is analyzed in relation to the development of a unified educational environment for training general practitioners and internists. Within the unified educational environment for training general practitioners and internists, academic schools of internal and preventive medicine act as a system-forming factor, ensuring the implementation of the Forum's guiding idea: "A Unified Educational Environment Is a Vector for the Development of Specialist Professionalism".
- 22 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (4S) , 4737
Open AccessAcademic schools of internal and preventive medicine: vectors for the development of physician professionalism
This article defines the role of academic schools of internal and preventive medicine in the unified educational environment for training physicians in the field of internal medicine. The 5 th International Research and Practice Forum "Academic Schools of Internal and Preventive Medicine" is analyzed in relation to the development of a unified educational environment for training general practitioners and internists. Within the unified educational environment for training general practitioners and internists, academic schools of internal and preventive medicine act as a system-forming factor, ensuring the implementation of the Forum's guiding idea: "A Unified Educational Environment Is a Vector for the Development of Specialist Professionalism".
- 14 October 2024
- Published by Bionika Media in Nephrology
- Vol. 3_2024
Age- and gender-related characteristics of chronic kidney disease in residents of the Subpolar North
- 14 October 2024
- Published by Bionika Media in Nephrology
- Vol. 3_2024
Age- and gender-related characteristics of chronic kidney disease in residents of the Subpolar North
- 17 April 2024
- Published by LLC M-Center in Суицидология
- Vol. 15 (01(54))
Дротаверин среди средств суицидальных действий
- 17 April 2024
- Published by LLC M-Center in Суицидология
- Vol. 15 (01(54))
Дротаверин среди средств суицидальных действий
- 27 December 2023
- Published by LLC M-Center in Суицидология
- Vol. 14 (04(53)) , 82-107
Суицидальное поведение при раке молочной железы у женщин
- 27 December 2023
- Published by LLC M-Center in Суицидология
- Vol. 14 (04(53)) , 82-107
Суицидальное поведение при раке молочной железы у женщин
- 12 May 2023
- Published by Bionika Media in Therapy
- Vol. 3_2023, 15-20
Indicators of systemic inflammation and state of the cardiovascular system in patients with chronic kidney disease
- 12 May 2023
- Published by Bionika Media in Therapy
- Vol. 3_2023, 15-20
Indicators of systemic inflammation and state of the cardiovascular system in patients with chronic kidney disease